FluoroPharma Medical, Inc. (FPMI) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerFluoroPharma Medical, Inc. (FPMI) trades at $0.0002. FluoroPharma Medical, Inc. is a biopharmaceutical company focused on developing molecular imaging pharmaceuticals for cardiology. Their lead product candidates target coronary artery disease (CAD) diagnosis and management. Sector: Healthcare.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for FPMI: FPMI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
FluoroPharma Medical, Inc. (FPMI) Healthcare & Pipeline Overview
FluoroPharma Medical, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of molecular imaging pharmaceuticals, primarily targeting cardiology applications such as coronary artery disease (CAD) diagnosis. Their pipeline includes BFPET and CardioPET, imaging agents designed to improve CAD assessment and management, positioning them within the niche molecular imaging market.
What Is the Investment Thesis for FPMI?
FluoroPharma Medical, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's value hinges on the successful development and commercialization of its molecular imaging agents, BFPET and CardioPET, targeting the diagnosis of coronary artery disease (CAD). Positive Phase IIa trial results for CardioPET could serve as a significant catalyst, potentially attracting strategic partnerships or acquisition interest. However, the company's limited financial resources, small team, and reliance on clinical trial outcomes introduce substantial risks. The negative beta of -69.72 suggests an inverse correlation with the market, which may be misleading given the company's stage and specific risks. Investors should carefully weigh the potential upside against the inherent uncertainties of biopharmaceutical development and the company's OTC market listing.
Based on FMP financials and quantitative analysis
FPMI Key Highlights
FluoroPharma Medical, Inc. focuses on molecular imaging pharmaceuticals for cardiology, specifically coronary artery disease (CAD).
- BFPET, a key product candidate, has completed Phase I clinical trials for stress-testing in CAD patients.
- CardioPET, another product candidate, is in Phase IIa clinical trials to assess myocardial blood flow and metabolism in CAD patients.
- The company has license agreements with Massachusetts General Hospital and Sinotau USA.
- FluoroPharma Medical, Inc. has a market capitalization of $0.00B, indicating its small size and early stage of development.
Who Are FPMI's Competitors?
FPMI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 69 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FPMI's Key Strengths?
Proprietary molecular imaging technology
- Focus on a specific therapeutic area (cardiology)
- Clinical data supporting the efficacy of their products
- Experienced management team
What Are FPMI's Weaknesses?
Limited financial resources
- Small team
- Reliance on clinical trial outcomes
- OTC market listing
What Are the Key Risks for FPMI?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for BFPET or CardioPET could significantly impact the company's value.
- Limited financial resources and small team pose challenges to product development and commercialization.
- Competition from established players in the medical imaging market.
- Regulatory hurdles and delays in obtaining FDA approval.
- OTC market listing increases the risk of price volatility and manipulation.
What Are FPMI's Competitive Advantages?
- Proprietary molecular imaging technology
- Patent protection for key product candidates
- Clinical data supporting the efficacy of their products
- Established relationships with key opinion leaders in cardiology
What Does FPMI Do?
Founded in 2003 and headquartered in Montclair, New Jersey, FluoroPharma Medical, Inc. is a biopharmaceutical company focused on the development of molecular imaging pharmaceuticals, with a particular emphasis on cardiology. The company's mission is to improve the diagnosis and management of cardiovascular diseases through advanced imaging technologies. Its lead product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial for stress-testing in patients with suspected or proven coronary artery disease (CAD), and CardioPET, a molecular imaging agent currently in Phase IIa clinical trials to assess myocardial blood flow and metabolism in CAD patients. FluoroPharma operates through license agreements with institutions like Massachusetts General Hospital and Sinotau USA, and has established clinical research agreements with Pharmaceutical Product Development, LLC, and Cardiovascular Imaging Technologies. The company's focus on molecular imaging in cardiology aims to provide clinicians with enhanced diagnostic tools for better patient outcomes. Despite its small size, with only 4 employees, FluoroPharma is actively pursuing clinical development and partnerships to advance its pipeline.
What Products and Services Does FPMI Offer?
- Develop molecular imaging pharmaceuticals.
- Focus on cardiology applications.
- Create imaging agents for coronary artery disease (CAD) diagnosis.
- Conduct clinical trials to assess the safety and efficacy of their products.
- Seek regulatory approval for their products from the FDA.
- Commercialize their products through partnerships or direct sales.
How Does FPMI Make Money?
- Develop and patent novel molecular imaging agents.
- Conduct clinical trials to demonstrate safety and efficacy.
- License or partner with larger pharmaceutical companies for commercialization.
- Generate revenue through licensing fees, milestone payments, and royalties.
What Industry Does FPMI Operate In?
FluoroPharma Medical, Inc. operates within the biotechnology industry, specifically targeting the molecular imaging segment within cardiology. The market for cardiovascular imaging is growing, driven by the increasing prevalence of heart disease and the demand for more accurate diagnostic tools. Competition includes established players in medical imaging and other biotechnology companies developing novel diagnostic agents. FluoroPharma's success depends on its ability to differentiate its products through superior efficacy, safety, and cost-effectiveness. The company's focus on CAD diagnosis positions it within a critical area of unmet medical need.
Who Are FPMI's Key Customers?
- Cardiologists
- Hospitals and imaging centers
- Patients with suspected or proven coronary artery disease (CAD)
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
FluoroPharma Medical, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Montclair, US. The company is led by CEO Edward L. Lyons Jr.. FPMI has traded publicly since 2011.
Key Financial Metrics
Return on equity for FluoroPharma Medical, Inc. stands at 22.7%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
FluoroPharma Medical, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Earnings Track Record
FluoroPharma Medical, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 22.7% below estimates on average.
Insider Activity
10 transactions · 6 purchases, 0 sales, 4 other transactions · 1 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
FPMI Financials
FPMI Latest News
No recent news available for FPMI.
FPMI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for FPMI.
Price Targets
Wall Street price target analysis for FPMI.
FPMI MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for FPMI; grades run from A+ (80-100) to F (below 30).
Leadership: Edward L. Lyons Jr.
Unknown
Information on Edward L. Without further information, it is impossible to provide details on his career history, education, or previous roles.
Track Record: Information on Edward L. Lyons Jr.'s track record is not available in the provided data. Without further information, it is impossible to provide details on key achievements, strategic decisions, or company milestones under his leadership.
FPMI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that FluoroPharma Medical, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. This tier is generally reserved for companies with distressed financials, early-stage ventures, or those that choose not to comply with stricter reporting standards.
- OTC Tier: OTC Other
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price manipulation
- Higher risk of fraud or scams
- Lack of regulatory oversight
- Verify the company's legal registration and compliance status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the company's capital structure and potential dilution.
- Monitor trading activity and price volatility.
- Consult with a qualified financial advisor.
- Existence of a physical headquarters and contact information
- Presence of a management team and board of directors
- Patents or intellectual property related to their technology
- Agreements with reputable institutions like Massachusetts General Hospital
- Completion of Phase I and Phase IIa clinical trials
Common Questions About FPMI (Healthcare)
What do analysts say about FPMI stock?
As of March 18, 2026, there is no readily available analyst coverage for FluoroPharma Medical, Inc. This lack of coverage is typical for companies trading on the OTC market with a small market capitalization.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is limited due to the company's OTC listing and limited analyst coverage.
- Financial data is based on available information and may not be comprehensive.